克隆T细胞丢失和新抗原逃逸介导的肺癌对TIL治疗的耐药性。

IF 28.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2025-05-21 DOI:10.1038/s43018-025-00947-w

{"title":"克隆T细胞丢失和新抗原逃逸介导的肺癌对TIL治疗的耐药性。","authors":"","doi":"10.1038/s43018-025-00947-w","DOIUrl":null,"url":null,"abstract":"By tracking tumor antigens and tumor-reactive T cell clones in serial tumor and blood samples, we identify key mechanisms of resistance to tumor-infiltrating lymphocyte (TIL) therapy of lung cancer. Loss of antitumor reactivity and exhaustion by infused TILs was associated with therapy resistance. New tumors that emerged lacked the original antigens or tumor-reactive T cells, which suggests adaptive resistance.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"6 5","pages":"749-750"},"PeriodicalIF":28.5000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Resistance to TIL therapy in lung cancer mediated by clonal T cell loss and neoantigen escape\",\"authors\":\"\",\"doi\":\"10.1038/s43018-025-00947-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"By tracking tumor antigens and tumor-reactive T cell clones in serial tumor and blood samples, we identify key mechanisms of resistance to tumor-infiltrating lymphocyte (TIL) therapy of lung cancer. Loss of antitumor reactivity and exhaustion by infused TILs was associated with therapy resistance. New tumors that emerged lacked the original antigens or tumor-reactive T cells, which suggests adaptive resistance.\",\"PeriodicalId\":18885,\"journal\":{\"name\":\"Nature cancer\",\"volume\":\"6 5\",\"pages\":\"749-750\"},\"PeriodicalIF\":28.5000,\"publicationDate\":\"2025-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s43018-025-00947-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cancer","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s43018-025-00947-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

通过跟踪肿瘤和血液样本中的肿瘤抗原和肿瘤反应性T细胞克隆，我们确定了肺癌肿瘤浸润淋巴细胞（TIL）治疗耐药的关键机制。输注TILs的抗肿瘤反应性丧失和衰竭与治疗抵抗有关。出现的新肿瘤缺乏原始抗原或肿瘤反应性T细胞，这表明适应性抵抗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Resistance to TIL therapy in lung cancer mediated by clonal T cell loss and neoantigen escape

查看原文本刊更多论文

Resistance to TIL therapy in lung cancer mediated by clonal T cell loss and neoantigen escape

By tracking tumor antigens and tumor-reactive T cell clones in serial tumor and blood samples, we identify key mechanisms of resistance to tumor-infiltrating lymphocyte (TIL) therapy of lung cancer. Loss of antitumor reactivity and exhaustion by infused TILs was associated with therapy resistance. New tumors that emerged lacked the original antigens or tumor-reactive T cells, which suggests adaptive resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.